BRAF and neoplasm: Interestingly, other patient baseline characteristics such as tumor load (S100/LDH), age, sex, BRAF mutation status, pretreatments, and treatment regime (PD-1 antibody vs. ipi/nivo) did not significantly impact PFS, however this may merely lie in the relatively low patient number of this retrospective study.